Matulane (procarbazine hydrochloride) / Leadiant Biosci - LARVOL DELTA

Epcoritamab monotherapy provides superior efficacy vs non–anthracycline-containing regimens in newly diagnosed elderly DLBCL patients deemed unsuitable for anthracycline-containing regimens: A match-adjusted comparative efficacy analysis (ASH 2025) - P2 | "Non-AC CITs included rituximab (R)-cyclophosphamide, doxorubicin, vincristine, prednisone [R-CEOP]/R-cyclophosphamide, vincristine, prednisone [R-CVP]/R-cyclophosphamide, etoposide, prednisone, procarbazine [R-CEPP]), bendamustine and rituximab (BR), and other combination regimens. Fixed-duration epcor mono demonstrated significantly superior OS vs non-AC regimens in newly diagnosed elderly and/or frail DLBCL pts deemed unsuitable for anthracyclines. These findings support epcor mono as a potential 1L chemo-free treatment option for newly diagnosed DLBCL pts unsuitable for AC regimens."

Clinical • Monotherapy • Diffuse Large B Cell Lymphoma • Large B Cell Lymphoma • Palliative care

The genomic differences in hispanic vs non hispanic patients with primary central nervous system lymphoma (ASH 2025) - "The most used treatment regimen was RMPV (Rituximab, Methotrexate, vincristine and Procarbazine). We identified high rate of somatic mutations in our sample with MYD 88 being the most common mutation, except in EBV-positive PCNSL, which is consistent with previous studies reporting mutual exclusivity between MYD88 L265P and EBV-associated PCNSL. Samples from non-Hispanic patients closely resembled to C3 cluster, which may suggest a potential association between non-Hispanic ethnicity and poorer survival in our cohort. However, due to the limited sample size, no conclusions can be drawn."

Clinical • Tumor mutational burden • Brain Cancer • CNS Lymphoma • CNS Tumor • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • CD79B • CDKN2A • EP300 • FBXL16 • MYD88 • PIM1 • PRDM1 • TMB

Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL) (ASH 2025) - "R-MPV/i induction regimen was well tolerated and resulted in improved complete responserates. The study met the primary endpoint of achieving a CRR of >80% after completion of R-MVP/i."

Combination therapy • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Thrombocytopenia

Treatment intensity and region of diagnosis affect survival in primary CNS lymphoma in England: A national cohort study from the uncover project. (ASH 2025) - "Intensive HD-MTX regimens were defined as including high dose cytarabine with or without thiotepa. HD-MTX alone orwith less intensive agents such as procarbazine were considered non-intensive...Patients receiving urgent chemotherapy had worse OS. Patients who undergoASCT experience have very good outcomes, although its application as first-line consolidation for PCNSLvaries markedly between regions, potentially contributing to geographical variation in survival."

CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma

Comparative analysis of consolidation strategies after induction chemotherapy in primary central nervous system lymphoma (ASH 2025) - "A total of 394 patients received HD-MTX-based induction: HD-MTX alone(n=130), methotrexate/procarbazine/vincristine (MPV, n=68), or rituximab-MPV (R-MPV, n=123)...Patients were categorized into five consolidation strategies:HDC-ASCT (n=160), whole brain radiotherapy (WBRT, n=14), high-dose cytarabine (Ara-C, n=83),etoposide/Ara-C (EA, n=34), and observation without consolidation (n=26)... In this large, single-center cohort with long-term follow-up, HDC-ASCT was the onlyconsolidation strategy that provided a significant survival benefit in patients with PCNSL. These findingssuggest limited benefit from reduced-intensity chemotherapy or WBRT as consolidation therapy. Ourresults highlight the need for alternative effective strategies for PCNSL patients who are not eligible forHDC-ASCT."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma

Clinical outcomes associated with conditioning regimens in patients with primary central nervous system lymphoma undergoing consolidation autologous stem cell transplantation (ASH 2025) - "This study compared clinical outcomes ofconsolidation ASCT according to conditioning regimens: thiotepa/busulfan/cyclophosphamide (TBC),busulfan/thiotepa (BuTT), and non-thiotepa regimens. This retrospective study included 160 newly diagnosed PCNSL patients treated at Asan MedicalCenter from 2004 to 2023 who responded to HD-MTX-based induction chemotherapy and proceeded toconsolidation ASCT. Induction regimens included HD-MTX, HD-MTX/procarbazine/vincristine (MPV), orrituximab-MPV (R-MPV). Patients were categorized by conditioning regimen: non-thiotepa(busulfan/cytarabine/etoposide[BuCyE], busulfan/melphalan/etoposide[BuMelE], orBCNU/etoposide/cytarabine/melphalan[BEAM]; n=28), TBC (n=71), and BuTT (n=61)... This study demonstrated that thiotepa-based conditioning regimens were associated withsuperior survival outcomes compared to non-thiotepa regimens for consolidation HDC-ASCT in PCNSLpatients. Among thiotepa-based regimens, BuTT and TBC showed comparable survival..."

Clinical • Clinical data • CNS Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Central Nervous System Lymphoma • Respiratory Diseases • Septic Shock • Transplantation

Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: A multicenter retrospective study (CoNSensus Study) (ASH 2025) - "In the intensive treatment cohort, 229 pts (69.4%) received rituximab (R) containing therapy. Most pts(272 pts, 82.4%) received HD-MTX based regimens as salvage therapy at first cycle, including HD-MTX ± R(52.2%) and MPV (HD-MTX, procarbazine and vincristine) ± R (46.7%). The remaining 58 pts (17.6%)received non-HD-MTX-based regimens, including HD-cytarabine-based (60.4%), CHOP-like (8.6%) andplatinum-based regimens (12.1%)...Pts who received busulfanand thiotepa (BuTT) conditioning (n = 23) showed better outcomes than those who received non-BuTTconditioning (n = 28) (3-year OS: 87.5% vs. 66.0%, p = 0.033). Although HD-MTX-based regimens were most frequent, this study revealed heterogeneity in first-linesalvage therapies for rSCNSL, highlighting the need for optimal tretament strategies. Addition of R andconsolidative HDT/ASCT (particularly BuTT) might be associated with improved OS and PFS."

Retrospective data • B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis (ASH 2025) - "First-line treatments were mainly HD-MTX alone (38%),HD-MTX + temozolomide (17%), or vincristine + procarbazine (12%)...Twelve patients (29%) underwent consolidative autologoustransplant, most commonly with thiotepa/carmustine (TT/BCNU, 69%) or BEAM conditioning (25%).Median duration of follow-up was 10.4 months... Forty-two pts met inclusion criteria. Median age was 57 (range 19–77), 69% were male, and 79%were white. Most (69%) had ECOG 0–1."

Retrospective data • CNS Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Solid Organ Transplantation • T Cell Non-Hodgkin Lymphoma • ALK • DNMT3A • TP53

Fertility outcomes following beacopp and ebeacopp chemotherapy in Hodgkin's lymphoma: A systematic review (ASH 2025) - "It can beeffectively treated with bleomycin sulfate, etoposide phosphate, doxorubicin hydrochloride (Adriamycin),cyclophosphamide, vincristine sulfate (Oncovin), procarbazine hydrochloride, and prednisone (BEACOPP)and escalated-BEACOPP chemotherapy. HL treatment can be done with BEACOPP/ eBEACOPP, but it can result in significant gonadotoxicity. Bothmale and female patients showed signs of infertility, with significant hormonal disturbances. PET-adapted regimens reduced POI and improved recovery of gonadal function in both sexes; manysurvivors, especially young patients with fertility preservation, were able to achieve pregnancies andparenthood."

Review • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infertility • Lymphoma • Sexual Disorders • Women's Health

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis (ASH 2025) - "The eBEACOPDac regimen, which replaces procarbazine with dacarbazine, isfavoured in some countries due to reduced gonadal and hematologic toxicity, with similar survival rates(Santarsieri, Lancet Oncol 2025)...Most patientsreceived conventional combination 2L chemotherapy (chemo, n=55; 76%), with gemcitibine,dexamethasone and cisplatin (GDP) most frequently used (n=48; 67%). 17 patients (24%) received 2Ltargeted agents: pembro-GVD (n=8), BV-DHAC (n=5), BV-nivo (n=2), pembro-ICE (n=1) and BrentuximabVedotin (BV) monotherapy (n=1)... For R/R HL after 1L eBEACOPDac, patients treated with 2L chemo have inferior outcomes compared topatients who relapse after ABVD. This informs our discussions with patients who relapse after 1LeBEACOPDac when consenting to 2L treatment. The use of 2L targeted agents was associated withsubstantially better outcomes, with a 47% difference in 2-yr PFS, which is unlikely to be attributable todifferences in baseline characteristics alone."

Adverse events • Clinical • Real-world • Real-world evidence • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients (ASH 2025) - "Induction regimens included 1) HD-MTX, temozolomide, and rituximab (MTR, 36%); 2) HD-MTX, procarbazine, and vincristine (MPV/variants, 33%); 3) HD-MTX, rituximab (25%); 4) HD-MTXalone/other (4%)...Cons regimens includedcytarabine (43%), etoposide+cytarabine (25%), radiation (22%), cytarabine+X (8%) and others (2%). Maintincluded rituximab-based therapy (26%), HD-MTX (22%), temozolomide (18%), BTK inhibitors (BTKi) (16%),HD-MTX+BTKi (3%), lenalidomide (14%) and other (3%)...Despite heterogeneous post-induction approaches, outcomes were similar across strategies, andinstitutional preference largely determined treatment choice, highlighting the absence of standardizedcare pathways. Given comparable efficacy, lower-intensity, less toxic regimens may be appropriate forthis vulnerable population."

Clinical • Alzheimer's Disease • CNS Lymphoma • Cognitive Disorders • Dementia • Depression • Epilepsy • Febrile Neutropenia • Geriatric Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Osteoporosis • Primary Central Nervous System Lymphoma • Psychiatry • Rheumatology • Transplantation

Dose Escalation shows no benefit compared to continuing ABVD in Hodgkin's lymphoma patients with an interim PET deauville score of 4 (ASH 2025) - "However, in resource-limited regions, escalating to BEACOPP can be costly, challenging, and may not be readily available.Moreover, procarbazine is not avaliable in different regions in Latin America, including Brazil, andescalation should use Dacarbazine in this context...The primary endpoint was progression freesurvival and secondary endpoint was complete response (CR) rate after initial therapy. Among 218 newly diagnosed patients with cHL, 31 (14%) were identified with a DS of 4 on iPET.The median age was 29 years (range, 20-74), with 58% female and 64.5% having advanced-stage disease.Initial treatment predominantly consisted of ABVD, except for one patient treated with AVD due toconcerns on pulmonary toxicity of bleomycin... This real-world study demonstrates that escalating treatment to BEACOP-DAC for all patientswith cHL and a DS of 4 did not provide significant benefit regarding treatment response, R/R rates or PFS,as compared to continuing with ABVD/AVD. We..."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies (ASH 2025) - "Patients deemed adequately fit were assigned to receive the standard combination of HDMTX,procarbazine, and rituximab as induction therapy...Patients ineligible for HDMTX wereassigned to receive concomitant whole-brain radiotherapy, temozolomide, and rituximab as inductiontherapy, followed by maintenance temozolomide (Part B)...The 3-year OS was 44 (±16%) forprocarbazine and 54 (±14%) for lenalidomide... Risk of treatment failure (in terms of dropout and survival rates) appeared higher comparedto the PRIMAIN trial. Discrepancies in feasibility and efficacy between PRIMAIN and FIORELLA trialsgenerate some concerns about generalization of results of PCNSL trials among different geographicalregions.These unexpected outcomes offer several valuable lessons on the incorporation of comorbidity indexesinto trial eligibility/stratification and the relevance of interim analyses to inform ethical decisions early."

Clinical • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Subarachnoid Hemorrhage

Improving outcomes with nivolumab consolidation among older patients (≥65) with previously untreated primary CNS lymphoma (ASH 2025) - P1 | "Induction chemotherapy regimens included 36% R-MPV (rituximab, methotrexate,procarbazine, and vincristine), 21% MRT (methotrexate, rituximab, and temozolomide), 21% MR(methotrexate and rituximab), and 7% MATRix (methotrexate, cytarabine, thiotepa, and rituximab).Following induction chemotherapy, 64% achieved a complete response (CR), 29% achieved a partialresponse (PR), and 7% had a stable disease (SD)... This study demonstrates favorable safety and clinical outcomes with nivolumab consolidationin older PCNSL patients unsuitable for ASCT or WBRT. No DLTs were observed during the safety run-inphase, and there were no unexpected toxicities associated with nivolumab, although one earlydiscontinuation occurred due to Stevens-Johnson syndrome, a rare but known AE of nivolumab. Overall,the absence of DLTs and encouraging survival outcomes support further investigation."

Clinical • IO biomarker • Alzheimer's Disease • CNS Lymphoma • Cognitive Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Steven-Johnson Syndrome

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL) (ASH 2025) - P1/2 | "Background : With standard high-dose methotrexate (HDMTX) and cytarabine (HDAraC)-basedinductions, half of the patients achieved complete response (CR)...Responders received two cycles of HDAraCfollowed by HD thiotepa-busulfan and ASCT... Both arms met the predetermined threshold of efficacy with 86% and 82% of CR/CRurates in the lenalidomide and ibrutinib arm, respectively. R-MPV plus a BTK-inhibitor or animmunomodulatory drug constitutes an interesting first-line induction for PCNSL patients up to 65 years.Correlation of patient, disease and lymphoid subpopulations characteristics with response in eachtreatment arm will be explored to guide the choice of the targeted therapy. Ancillary studies regardingthe prognostic impact of baseline and end of induction levels of cytokines in the CSF, ctDNA inplasma/CSF and radiomic features, as biomarkers of response, are planned."

Clinical • IO biomarker • P2 data • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Hepatology • Lymphoma • Mental Retardation • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Steven-Johnson Syndrome • CD4 • ICOS • PD-1

Comparing Isocitrate Dehydrogenase Inhibitors with Procarbazine, Lomustine, and Vincristine Chemotherapy for Oligodendrogliomas. (PubMed, Cancers (Basel)) - "IDH inhibitors such as vorasidenib have demonstrated promising efficacy and more favorable tolerability profiles, but a paucity of comparative data across therapeutic classes limits optimal treatment decision-making. Prospective head-to-head trials are essential for defining the optimal therapeutic sequence in this evolving treatment landscape. In the interim, we provide a recommend approach for current use."

Journal • Review • Brain Cancer • Glioma • Hematological Disorders • Oligodendroglioma • Oncology • Solid Tumor

An atlas of ex vivo drug sensitivity profiles in 666 clinical glioblastoma samples revealed distinct survival-associated networks (SNO 2025) - P=N/A | "Eleven drugs were tested, including DNA-damaging agents (lomustine, carboplatin, temozolomide, procarbazine, irinotecan, etoposide) and targeted agents (abemaciclib, dabrafenib, osimertinib, rucaparib, trametinib). Longitudinal sampling revealed dynamic changes in drug sensitivity, reflecting evolutionary tumor biology. This ex vivo drug sensitivity atlas reveals distinct, non-random survival-associated clustering patterns that reflect underlying glioblastoma cellular physiologies and may inform future clinical trial designs."

Preclinical • Brain Cancer • Glioblastoma • Glioma • Solid Tumor

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov) - P2 | N=65 | Recruiting | Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

R-MPV Followed by Maintenance MPV in Elderly Patients with Newly Diagnosed Primary CNS Lymphoma (SNO 2025) - "We treated ePCNSL with induction immunochemotherapy consisting of rituximab (R), HD-MTX, procarbazine, and vincristine (R-MPV), followed by maintenance chemotherapy with MPV... These findings suggest that maintenance chemotherapy with MPV may improve performance status, neurocognitive function, and overall prognosis in elderly patients with PCNSL."

Clinical • Cardiovascular • CNS Lymphoma • Hematological Malignancies • Lymphoma • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Renal Disease

Patterns of care and clinical outcomes of patients with IDH-mutant high-grade glioma in the United States from 2014-2023: a real-world analysis of the Tempus Lens database (SNO 2025) - "The most common treatment options administered at recurrence for astrocytoma were: re-treatment with temozolomide (13, 20%), bevacizumab (9, 14%), with lomustine, re-irradiation therapy, clinical trial and IDH inhibitors as additional less common alternatives. At recurrence, oligodendrogliomas were most frequently treated with bevacizumab (5, 36%), procarbazine and lomustine (3, 21%), or PCV (2, 14%). Additional findings, including molecular heterogeneity and survival data will be presented at the meeting. IDHmHGG represents a heterogeneous group of tumors with no clear standard-of-care upon recurrence after initial treatment."

Clinical • Clinical data • Real-world • Real-world evidence • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioma • High Grade Glioma • Oligodendroglioma • Solid Tumor

Ibrutinib in combination with Rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL) (SNO 2025) - "For the 25 completing R-MVP/i, 16 received Ara-C consolidation, 7 ASCT, and 1 rituximab maintenance. R-MPV/i induction regimen resulted in improved complete response rates and met the primary endpoint."

Combination therapy • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma

Real-world outcomes in older patients with primary CNS lymphoma treated by R-MPV treatment without whole brain radiotherapy. (SNO 2025) - "We evaluated the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) for elderly patients with PCNSL avoiding routine WBRT. We evaluated ≥60-year-old patients with newly diagnosed PCNSL who received high dose MTX (HD-MTX) based regimen and R-MPV with or without WBRT from January 2008 to January 2024 at Kobe University Hospital... In PCNSL patients over 60 years old, R-MPV therapy avoiding WBRT had a better outcome than the induction therapy with WBRT. Moreover, high CSF IL-10 levels were an important factor in the progression of brain atrophy associated with WBRT. Based on the results, we should evaluate appropriate consolidation therapy (reduced-dose WBRT ≤24 Gy or autologous hematopoietic stem cell transplantation) in the future."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • IL10

Ibrutinib in combination with Rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL) (WFNOS 2025) - "For the 25 completing R-MVP/i, 16 received Ara-C consolidation, 7 ASCT, and 1 rituximab maintenance. R-MPV/i induction regimen resulted in improved complete response rates and met the primary endpoint."

Combination therapy • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma

Single institution experience with romiplostim for chemotherapy-induced thrombocytopenia in gliomas (SNO 2025) - "Background: Cytotoxic chemotherapy such as temozolomide, lomustine, procarbazine and platinum agents are the mainstay of glioma treatment. This single institution review provides evidence for the use of romiplostim to treat CIT in patients with glioma previously treated with temozolomide with no documented adverse events. Further studies are needed to examine if higher doses of romiplostim may be required to prevent CIT and continue chemotherapy without dose reduction."

Clinical • Brain Cancer • Glioma • Hematological Disorders • Solid Tumor • Thrombocytopenia • Thrombosis